Oncolytics Biotech Inc (ONCY): NEWS -- Oncolytics Biotech® Reports...

Replies (1) Next 10 Prev Next

Send PM Follow Ignore

Re: None

Monday, 11/07/2022 9:11:58 AM

Monday, November 07, 2022 9:11:58 AM

NEWS -- Oncolytics Biotech® Reports Third Quarter 2022 Financial Results and Recent Operational Highlights

SAN DIEGO and CALGARY, AB, Nov. 7, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced recent operational highlights and financial results for the third quarter ended September 30, 2022. All dollar amounts are expressed in Canadian currency unless otherwise noted.

Follow link to view entire Press Release: https://www.prnewswire.com/news-releases/oncolytics-biotech-reports-third-quarter-2022-financial-results-and-recent-operational-highlights-301669590.html

Keep Last Read

Replies (1) Next 10 Prev Next

Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2026 01:03:22 PM
Oncolytics Biotech® to Present Data at ASCO 2026 Reinforcing Pelareorep’s Potential Across Gastrointestinal Tumors • GlobeNewswire Inc. • 05/22/2026 01:00:00 PM
Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2026 08:30:07 PM
"Cold" Solid Tumors Become the Proving Ground for a New Generation of Engager and Immune-Priming Therapies • GlobeNewswire Inc. • 05/14/2026 02:55:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 05/04/2026 01:03:46 PM
Oncolytics Biotech® Reports Durable Responses in Second-Line RAS-Mutant MSS Colorectal Cancer • GlobeNewswire Inc. • 05/04/2026 01:00:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 04/27/2026 12:16:41 PM
Oncolytics Aligns with FDA on Planned Pivotal Anal Cancer Study • GlobeNewswire Inc. • 04/27/2026 12:10:00 PM
Form F-10POS - Post-effective amendment to a F-10EF registration • Edgar (US Regulatory) • 04/08/2026 09:04:36 PM
Form AW - Amendment Withdrawal Request • Edgar (US Regulatory) • 04/08/2026 09:03:47 PM

Go Ad-Free